Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

U.S. drug distributors prevail in $2.5 billion West Virginia opioid case

Stock Markets Jul 04, 2022 11:15PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017. REUTERS/Bryan Woolston/File Photo

By Nate Raymond

(Reuters) -Major U.S. drug distributors McKesson Corp (NYSE:MCK), AmerisourceBergen (NYSE:ABC) Corp and Cardinal Health Inc (NYSE:CAH) are not responsible for fueling an opioid epidemic in a part of West Virginia, a federal judge ruled on Monday.

U.S. District Judge David Faber rejected efforts by the city of Huntington and Cabell County to force the country's three largest pharmaceutical distributors to pay $2.5 billion to address a drug crisis prompted by a flood of addictive pills in their region.

But following a months-long trial that ended last year, Faber said the companies did not cause any oversupply of opioids, saying doctors' "good faith" prescribing decisions drove the volume of painkillers they shipped to pharmacies.

While the companies from 2006 to 2014 shipped 51.3 million opioid pills to retail pharmacies in the communities, "there is nothing unreasonable about distributing controlled substances to fulfill legally written prescriptions," Faber wrote.

"The opioid crisis has taken a considerable toll on the citizens of Cabell County and the city of Huntington," he wrote. "And while there is a natural tendency to assign blame in such cases, they must be decided not based on sympathy, but on the facts and the law."

Steve Williams, Huntington's mayor, in a statement called the decision "a blow to our city and community." The city had sought to force the companies to help fund opioid treatment programs.

The companies welcomed the ruling, which AmerisourceBergen said struck down the notion that the distribution of U.S. Food and Drug Administration-approved drugs to licensed health care providers could be deemed a public nuisance.

Cardinal Health and McKesson in separate statements said the distributors had maintained systems to prevent the diversion of opioids to illicit channels.

More than 3,300 lawsuits have been filed, largely by state and local governments, seeking to hold those and other companies responsible for an opioid abuse epidemic linked to more than 500,000 overdose deaths over the last two decades.

The distributors, along with drugmaker Johnson & (J&J (NYSE:JNJ)), last year agreed to pay up to $26 billion to resolve the thousands of lawsuits brought against them by state and local governments around the country.

But communities in hard-hit West Virginia opted against joining a national opioid settlement in favor of seeking a bigger recovery. Another trial pitting the distributors against West Virginia communities begins Tuesday in state court.

Monday's ruling adds to the mixed record for opioid cases that have gone to trial nationally, with courts in Oklahoma and California last year rejecting similar claims against drugmakers like J&J.

A federal jury in November found pharmacy chain operators CVS Health Corp (NYSE:CVS), Walgreens Boots Alliance (NASDAQ:WBA) Inc and Walmart (NYSE:WMT) Inc liable in a case filed by two Ohio counties. A New York jury found Teva Pharmaceutical Industries (NYSE:TEVA) Ltd liable in December in a case by the state and two counties.

U.S. drug distributors prevail in $2.5 billion West Virginia opioid case
 

Related Articles

Former Deutsche Bank co-CEO Anshu Jain dies
Former Deutsche Bank co-CEO Anshu Jain dies By Reuters - Aug 13, 2022

FRANKFURT (Reuters) - Anshu Jain, the former Deutsche Bank AG (NYSE:DB) co-chief executive officer, died early on Saturday at the age of 59 after a long illness, the bank said....

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email